

9 October 2026

To

BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: COHANCE

Dear Sir/Madam,

Subject: Disclosure regarding grant of ESOPs

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform that the Nomination and Remuneration Committee of the Company, at its meeting held today, i.e. on 9 October 2026, has approved the grant of employee stock options under the Company's ESOP schemes as detailed below:

1. grant of 2,60,194 stock options to the eligible employees of the Company under the Cohance Lifesciences Limited – Employee Stock Option Plan 2026 (the “ESOP 2026”);
2. grant of 6,14,594 stock options to the eligible employees of the Company under the Suven Pharmaceuticals Limited – Employee Stock Option Plan 2023 (the “ESOP 2023”);

The details required under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 on the above grants are enclosed herewith as **Annexure 1 and Annexure 2**.

Kindly take the above on record.

Thanking you

Yours faithfully,

For **Cohance Lifesciences Limited**
(formerly, Suven Pharmaceuticals Limited)
Sisira Kumar Mishra
Date: 2026.10.09
23:35:01 +05'30'

Company Secretary & Compliance Officer

Encl: as above

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSILC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com



Details of grant of employee stock options under the ESOP 2026

No	Particulars	Remarks
1	Brief details of Options granted	2,60,194 employee stock options (“ Options ”), which may be offered and granted in one or more tranches, each convertible into one equity share of the Company of face value of INR 1/-
2	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable)	Yes
3	Total number of shares covered by these options	The Options, upon exercise, shall result in allotment of 2,60,194 shares.
4	Pricing formula	The exercise price per option shall be decided by the Board or Nomination and Remuneration Committee and set out in the letter of grant. Provided that in any circumstances, the exercise price shall: (a) not be less than INR 325 (Rupees Three Hundred and Twenty Five only) for any grant that is made within 6 (six) months of the date of receipt of in-principle approval from the stock exchange following the approval of the ESOP 2026 by the shareholders of the Company, provided however that the grant to existing employees of the Company as on the effective date of the ESOP 2026 shall be made within 10 (ten) working days of the date of receipt of in-principle approval from the stock exchanges following the approval of the shareholders, at the exercise price of INR 325 (Rupees Three Hundred and Twenty Five only); or (b) in the case of any grant made after 6 (six) months of the date of receipt of in-principle approval from the stock exchanges following the approval of the shareholders, or any grant to existing employees made after 10 (ten) working days of receipt of in-principle approval from the stock exchanges as set out above, the exercise price shall not be at more than a 20% (twenty percent) discount to the average market price of the shares of the Company over a 21 (twenty-one) trading days’ period preceding one trading day prior to the grant date.
5	Options vested	Options granted shall vest not earlier than minimum period of 1 (one) year and not later than maximum period of 8 (eight) years from the date of grant, subject to conditions as set out in the grant letter as issued to respective employees. The Nomination and Remuneration Committee may at its discretion, subject to applicable laws, change the vesting schedule provided that such change is not detrimental in the interest of the employees.

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com



6	Time within which option may be exercised	The exercise period shall be up to 3 years from the date of vesting of options.
7	Options exercised	Not applicable
8	Money realized by exercise of options	Not applicable
9	The total number of shares arising as a result of exercise of option	Not applicable
10	Options lapsed	Not applicable
11	Variation of terms of options	Not applicable
12	Brief details of significant terms	Significant terms of the Options have been given in the ESOP 2026, which can be accessed on the website of the Company at https://www.cohance.com/wp-content/uploads/2026/07/ESOP-2026-Plan-23Jul26-Final.pdf
13	Subsequent changes or cancellation or exercise of such options	Not applicable
14	Diluted earnings per share pursuant to issue of equity shares on exercise of options	Not applicable

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSILC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com



Details of grant of employee stock options under the ESOP 2023

No	Particulars	Remarks
1	Brief details of Options granted	6,14,594 employee stock options (“Options”), which may be offered and granted in one or more tranches, each convertible into one equity share of the Company of face value of INR 1/-
2	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable)	Yes
3	Total number of shares covered by these options	The Options, upon exercise, shall result in allotment of 6,14,594 shares.
4	Pricing formula	All Options were granted at the exercise price of INR 495.
5	Options vested	Options granted shall vest not earlier than minimum period of 1 (one) year and not later than maximum period of 10 (ten) years from the date of grant, subject to conditions as set out in the grant letter as issued to respective employees. The Nomination and Remuneration Committee may at its discretion, subject to applicable laws, change the vesting schedule provided that such change is not detrimental in the interest of the employees.
6	Time within which option may be exercised	The exercise period shall be up to 3 years from the date of vesting of options.
7	Options exercised	Not applicable
8	Money realized by exercise of options	Not applicable
9	The total number of shares arising as a result of exercise of option	Not applicable
10	Options lapsed	Not applicable
11	Variation of terms of options	Not applicable
12	Brief details of significant terms	Significant terms of the Options have been given in the ESOP 2023, which can be accessed on the website of the Company at https://www.cohance.com/wp-content/uploads/2025/06/SuvenESOP2023Policy.pdf
13	Subsequent changes or cancellation or exercise of such options	Not applicable
14	Diluted earnings per share pursuant to issue of equity shares on exercise of options	Not applicable

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com

